Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 1, 2005, Pages 13-20

  Goyal, Deepak ^a   Choudhury, Anirban ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Breast; Coagulation; Gynaecological; Prophylaxis; Thrombosis

Indexed keywords

ANASTROZOLE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DALTEPARIN; DOXORUBICIN; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; TAMOXIFEN; TINZAPARIN; WARFARIN;

ADVANCED CANCER; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GYNECOLOGIC CANCER; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; HYPERCOAGULABILITY; LEG THROMBOSIS; MORBIDITY; MORTALITY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; VAGINA CANCER;

EID: 14644444203     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200502000-00004     Document Type: Review

References (64)

1. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87:575-579.
2. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3:27-34.
3. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonwealth 1974; 81:311-316.
4. Crandon AJ, Koutts J. Incidence of post-operative deep vein thrombosis in gynaecological oncology. Aust NZ J Obstet Gynaecol 1983; 23:216-219.
5. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479-484.
6. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89:1673-1682.
7. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25:137-145.
8. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54:1264-1268.
9. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886-889.
10. von Tempelhoff GF, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77:456-461.
11. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25:147-155.
12. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20:3276-3281.
13. Otterson GA, Monahan BP, Harold N, et al. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101:406-412.
14. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79:2024-2027.
15. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14-31.
16. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983; 61:87-94.
17. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327:1128-1133.
18. Monreal M, Fernandez-Llamazares J, Perandreu J, et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78:1316-1318.
19. Lin JT. Thromboembolic events in the cancer patient. J Womens Health Larchmt 2003; 12:541-551.
20. Evans TR, Mansi JL, Sevan DH. Trousseau's syndrome in association with ovarian carcinoma. Cancer 1996; 77:2544-2549.
21. Deppisch LM, Fayemi AO. Non-bacterial thrombotic endocarditis: clinico-pathologic correlations. Am Heart J 1976; 92:723-729.
22. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol 2002; 20:4111-4114.
23. Green ST. Two unusual cardiac complications of gynaecological malignancy: myocardial metastases and non-infective thrombotic endocarditis. Br J Clin Pract 1990; 44:74-75.
24. Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990; 17:172-186.
25. Fisher DC, Sherrill GB, Hussein A, et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996; 18:193-198.
26. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41-44.
27. Blann AD, Lip GY. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res 2001; 101:321-327.
28. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4:465-473.
29. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74:278-281.
30. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349:109-111.
31. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78:133-136.
32. Gailus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997; 78:126-132.
33. von Tempelhoff GF, Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am 2000; 14:1151-1169.ix.
34. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(1 Suppl.):132S-175S.
35. Clarke-Pearson DL, Creasman WT, Coleman RE, et al. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984; 18:226-232.
36. Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001; 98:989-995.
37. Clarke-Pearson DL, Synan IS, Hinshaw WM, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63:92-98.
38. Clarke-Pearson DL, Synan IS, Dodge R, et al. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993; 168:1146-1153.
39. Clark-Pearson DL, DeLong E, Synan IS, et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990; 75:684-689.
40. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817-824.
41. Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12:1266-1271.
42. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage Il breast cancer. N Engl J Med 1988; 318:404-407.
43. Rogers JS, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6:276-281.
44. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63:1303-1307.
45. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 1998; 79:23-27.
46. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003; 98:1578-1586. A comprehensive review of the coagulopathic complications seen during various therapeutic interventions in patients with breast cancer.
47. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995; 311:977-980.
48. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14:2731-2737.
49. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.
50. Mannucci PM, Bettega D, Chantarangkul V, et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156:1806-1810.
51. Mamby CC, Love RR, Feyzi JM. Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994; 30:311-314.
52. Japan Breast Cancer Group. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group. Jpn J Cancer Res 1993; 84:455-461.
53. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
54. Prandoni P, Lensing AW, Piccioli A, et at. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-3488.
55. Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111:270-273.
56. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729-1735.
57. Lee AY, Levine MN5 Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153. A randomized controlled trial which demonstrated superiorit, of LMW heparin over conventional warfarin therapy in preventing recurrent venous thromboembolism.
58. Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158:2001-2003.
59. Hull R, Pineo GF, Mah AF, Brant RF. For the LITE investigators. A randomized trial evaluating long-term low-molecular weight heparin therapy for three months vs. intravenous heparin followed by wararin sodium in patients with current cancer. J Thromb Haemost 2003; 1(Suppl 1). Abstract P1373a.
60. Caine GJ, Lip GYH. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Arch Intern Med 2003; 163:1243-1244.
61. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22:1944-1948. The most recent study of LMW heparin in advanced cancer that failed to demonstrate any improved outcome in terms of survival.
62. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349:1713-1721.
63. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425-1434.
64. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639.